Rituximab can Decrease Proteinuria in Refractory Lupus Nephritis.
作者信息
Suh Chang-Hee
机构信息
Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea.
Department of Molecular Science and Technology, Ajou University, Suwon, Korea.
出版信息
J Rheum Dis. 2022 Apr 1;29(2):59-60. doi: 10.4078/jrd.2022.29.2.59.
Abstract
摘要
相似文献
1
Rituximab can Decrease Proteinuria in Refractory Lupus Nephritis.利妥昔单抗可降低难治性狼疮性肾炎的蛋白尿。
J Rheum Dis. 2022 Apr 1;29(2):59-60. doi: 10.4078/jrd.2022.29.2.59.
2
Single-dose rituximab in refractory lupus nephritis.单剂量利妥昔单抗治疗难治性狼疮肾炎。
Intern Med J. 2016 Aug;46(8):899-901. doi: 10.1111/imj.13136.
3
Analysis of the effectiveness and safety of rituximab in patients with refractory lupus nephritis: a chart review.利妥昔单抗治疗难治性狼疮性肾炎患者的有效性和安全性分析：一项病历回顾研究
Clin Rheumatol. 2016 Feb;35(2):517-22. doi: 10.1007/s10067-015-3166-9. Epub 2016 Jan 14.
4
Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis.利妥昔单抗治疗耐药性狼疮肾炎：快速进展性新月体性狼疮肾炎治疗失败。
Lupus. 2013 May;22(6):574-82. doi: 10.1177/0961203313483376. Epub 2013 Apr 30.
5
Oral supplementation of turmeric decreases proteinuria, hematuria, and systolic blood pressure in patients suffering from relapsing or refractory lupus nephritis: a randomized and placebo-controlled study.口服姜黄补充剂可减少复发或难治性狼疮肾炎患者的蛋白尿、血尿和收缩压：一项随机安慰剂对照研究。
J Ren Nutr. 2012 Jan;22(1):50-7. doi: 10.1053/j.jrn.2011.03.002. Epub 2011 Jul 13.
6
Combination of tacrolimus and mycophenolate mofetil in persistent proteinuria due to refractory childhood lupus nephritis.他克莫司与霉酚酸酯联合治疗儿童难治性狼疮性肾炎所致持续性蛋白尿
Int J Pediatr Adolesc Med. 2018 Sep;5(3):99-102. doi: 10.1016/j.ijpam.2018.08.001. Epub 2018 Aug 9.
7
Efficacy and safety of bortezomib in refractory lupus nephritis: a single-center experience.硼替佐米治疗难治性狼疮肾炎的疗效和安全性：单中心经验。
Lupus. 2020 Feb;29(2):118-125. doi: 10.1177/0961203319896018. Epub 2019 Dec 22.
8
Differences in rituximab use between pediatric rheumatologists and nephrologists for the treatment of refractory lupus nephritis and renal flare in childhood-onset SLE.儿科风湿病学家和肾脏病学家在治疗儿童发病的系统性红斑狼疮（SLE）患者难治性狼疮肾炎和肾危象时使用利妥昔单抗的差异。
Pediatr Rheumatol Online J. 2021 Aug 30;19(1):137. doi: 10.1186/s12969-021-00627-w.
9
Rituximab alone as induction therapy for membranous lupus nephritis: A multicenter retrospective study.利妥昔单抗单药作为膜性狼疮性肾炎的诱导治疗：一项多中心回顾性研究。
Medicine (Baltimore). 2017 Jul;96(27):e7429. doi: 10.1097/MD.0000000000007429.
10
Remission of refractory lupus nephritis with a protocol including rituximab.采用包含利妥昔单抗的方案使难治性狼疮性肾炎缓解。
Lupus. 2003;12(10):783-7. doi: 10.1191/0961203303lu453cr.
本文引用的文献
1
Initial Preserved Renal Function as a Predictor of Favorable Renal Response to Rituximab in Refractory or Relapsing Lupus Nephritis: A Single-center Cohort Study in Korea.初始肾功能作为难治性或复发性狼疮性肾炎患者对利妥昔单抗肾脏反应良好的预测指标：韩国一项单中心队列研究
J Rheum Dis. 2022 Jan 1;29(1):22-32. doi: 10.4078/jrd.2022.29.1.22.
2
Efficacy and safety of an anti-CD20 monoclonal antibody, rituximab, for lupus nephritis: A meta-analysis.抗 CD20 单克隆抗体利妥昔单抗治疗狼疮肾炎的疗效和安全性：一项荟萃分析。
Int J Rheum Dis. 2022 Feb;25(2):101-109. doi: 10.1111/1756-185X.14240. Epub 2021 Nov 23.
3
The lupus nephritis management renaissance.狼疮肾炎治疗的复兴。
Kidney Int. 2022 Feb;101(2):242-255. doi: 10.1016/j.kint.2021.09.012. Epub 2021 Oct 4.
4
Prognostic and Diagnostic Values of Novel Serum and Urine Biomarkers in Lupus Nephritis: A Systematic Review.新型血清和尿液生物标志物在狼疮肾炎中的预后和诊断价值：系统评价。
Am J Nephrol. 2021;52(7):559-571. doi: 10.1159/000517852. Epub 2021 Aug 13.
5
Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.与安慰剂相比，voclosporin治疗狼疮性肾炎的疗效和安全性（AURORA 1）：一项双盲、随机、多中心、安慰剂对照的3期试验。
Lancet. 2021 May 29;397(10289):2070-2080. doi: 10.1016/S0140-6736(21)00578-X. Epub 2021 May 7.
6
A panel of urinary proteins predicts active lupus nephritis and response to rituximab treatment.一组尿蛋白可预测狼疮性肾炎的活动期和对利妥昔单抗治疗的反应。
Rheumatology (Oxford). 2021 Aug 2;60(8):3747-3759. doi: 10.1093/rheumatology/keaa851.
7
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.两年随机对照试验研究贝利尤单抗治疗狼疮肾炎。
N Engl J Med. 2020 Sep 17;383(12):1117-1128. doi: 10.1056/NEJMoa2001180.
8
Urine and serum S100A8/A9 and S100A12 associate with active lupus nephritis and may predict response to rituximab treatment.尿液和血清 S100A8/A9 和 S100A12 与活动性狼疮肾炎相关，并且可能预测利妥昔单抗治疗的反应。
RMD Open. 2020 Jul;6(2). doi: 10.1136/rmdopen-2020-001257.
9
2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis.2019 年更新版欧洲抗风湿病联盟与欧洲肾脏学会-欧洲透析和移植学会（EULAR/ERA-EDTA）狼疮肾炎管理建议。
Ann Rheum Dis. 2020 Jun;79(6):713-723. doi: 10.1136/annrheumdis-2020-216924. Epub 2020 Mar 27.
10
Utilization of Biomarkers in Lupus Nephritis.生物标志物在狼疮肾炎中的应用。
Adv Chronic Kidney Dis. 2019 Sep;26(5):351-359. doi: 10.1053/j.ackd.2019.09.001.
Zotero 插件